ACSVL1 Inhibitors
1 drugsAbout ACSVL1
Acyl-CoA synthetase long-chain family member 1 (ACSVL1) is an enzyme that catalyzes the formation of fatty acyl-CoA, a crucial step in fatty acid metabolism. This process is essential for both fatty acid synthesis and degradation, playing a vital role in cellular energy production and lipid homeostasis.
While there is currently no genetic evidence directly linking ACSVL1 to specific diseases, its involvement in metabolic pathways makes it a relevant target for drug development. ACSVL1 represents a potentially valuable target for developing new therapeutic interventions aimed at restoring metabolic balance.
ACSVL1 is currently targeted by one FDA-approved drug, NEXLETOL, a small molecule approved in 2020 for metabolic indications. ESPERION THERAPS INC is the sole company with an approved drug for this target.
Top ACSVL1 Drugs
ESPERION THERAPS INC is the only company with an approved drug targeting ACSVL1.
Low competitive intensity suggests a potential opportunity, but also indicates possible challenges in target validation or market size.
ACSVL1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ACSVL1, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or peptides.
ACSVL1 Clinical Trials 33 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ACSVL1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 | 100% |
| Phase 2 | 7 | 5 | 0 | 2 | 100% |
| Phase 3 | 14 | 9 | 0 | 5 | 100% |
| Phase 4 | 5 | 3 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved ACSVL1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ACSVL1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
ACSVL1 Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for ACSVL1 was NEXLETOL in 2020.
Recent entry indicates growing interest, but a single approval suggests the target may not be fully saturated, leaving room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 15 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ACSVL1. A trial counts if an approved drug acting on ACSVL1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.